厄洛替尼联合吉西他滨对比吉西他滨单药治疗晚期胰腺癌:加拿大国家癌症研究所临床试验组III期试验
这项双盲国际III期试验将569例不可切除局部晚期或转移性胰腺癌患者随机分配至吉西他滨联合厄洛替尼组或吉西他滨联合安慰剂组,主要终点总生存期在厄洛替尼组显著延长(HR 0.82,中位6.24个月 vs 5.91个月),1年生存率亦更高(23% vs 17%),推荐厄洛替尼联合吉西他滨的剂量为100 mg/d。
要点
- 厄洛替尼联合吉西他滨较单药显著延长总生存期(HR 0.82,中位6.24个月 vs 5.91个月)
- 联合组1年生存率23% vs 17%(P=0.023),无进展生存期显著延长(HR 0.77)
- 该适应症推荐厄洛替尼剂量为100 mg/d
核心结论
- 该随机III期试验首次证明在吉西他滨基础上加用任何药物可统计学显著改善晚期胰腺癌生存。
- 该适应症推荐厄洛替尼联合吉西他滨的剂量为100 mg/d。
研究设计与样本
- 双盲、国际、III期随机对照试验,由加拿大国家癌症研究所临床试验组开展。
- 569例不可切除局部晚期或转移性胰腺癌患者按1:1随机分配至吉西他滨联合厄洛替尼(100或150 mg/d口服)或吉西他滨联合安慰剂。
- 主要终点为总生存期。
主要发现
- 意向性治疗分析显示厄洛替尼联合吉西他滨组总生存期显著延长,HR 0.82(95%CI 0.69-0.99;P=0.038,按分层因素校正;中位6.24个月 vs 5.91个月)。
- 厄洛替尼联合吉西他滨组1年生存率更高(23% vs 17%;P=0.023)。
- 厄洛替尼联合吉西他滨组无进展生存期显著更长,估计HR 0.77(95%CI 0.64-0.92;P=0.004)。
- 两组客观缓解率无显著差异,但厄洛替尼组更多患者疾病稳定。
- 厄洛替尼联合吉西他滨组部分不良事件发生率更高,但多为1级或2级。
关键数值与推荐
- 总生存期HR 0.82(95%CI 0.69-0.99;P=0.038),中位6.24个月 vs 5.91个月。
- 1年生存率23% vs 17%(P=0.023)。
- 无进展生存期估计HR 0.77(95%CI 0.64-0.92;P=0.004)。
- 该适应症推荐厄洛替尼剂量为100 mg/d。
临床怎么用
- 对于不可切除局部晚期或转移性胰腺癌患者,可在吉西他滨基础上加用厄洛替尼100 mg/d。
- 厄洛替尼联合吉西他滨组部分不良事件发生率更高,但多为1级或2级。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. PATIENTS AND METHODS: Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival. RESULTS: A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2. CONCLUSION: To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.
引用
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2023. PMID: 37847995. doi:10.1200/JCO.22.02770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。